Columbia Research Enhanced Mid Cap ETF
REMC · ETF
About REMC
- Issuer
- Columbia
- Expense ratio
- 0.32%
- Assets under management
- $5.82M
- Inception
- Dec 11, 2025
- Asset class
- Equity
- Website
- columbiathreadneedleus.com
REMC key statistics
- Price-earnings ratio
- 0.00
- Average volume
- 52
- Volume
- 6
- Open price
- $23.28
- High today
- $23.28
- Low today
- $23.28
- 52 Week high
- $23.76
- 52 Week low
- $19.83
Columbia Research Enhanced Mid Cap ETF (REMC) at a glance
Columbia Research Enhanced Mid Cap ETF (REMC) last traded at $23.28, with a price-to-earnings ratio of 0.00.
Volume so far is 6 shares, below the average of 52 shares a day.
Over the past year Columbia Research Enhanced Mid Cap ETF has ranged from $19.83 to $23.76, and now sits 88% of the way up that range.
REMC news
- Press releaseBusiness Wire
Most active stocks
Highest trading volume today
- EARIEntertainment Arts Research$0.0002+0.00%
- GTVHGolden Triangle Ventures$0.0002+100.00%
- TMSHTrans Global Assets$0.0003+20.00%
- RDARRaadr$0.0002+0.00%
- GPUSHyperscale Data$0.1689+34.05%
- SEIISharing Economy International$0.0002−33.33%
- ELMEElme Communities$1.77+0.57%
- SHFSSHF Holdings$0.1324−61.39%
- XXII22nd Century Group$0.1977−8.34%
- NBNDNetBrands$0.0006−40.00%
- NVDGraniteShares ETF Trust$4.19+0.96%
- HIRUHiru$0.0006+9.09%
Newly listed
Companies that went public in the past six weeks
- TCXBTCGX Acquisition Corp. II$10.49−0.10%
- CTYCITY THERAPEUTICS$20.77+0.00%
- IAMIambic Therapeutics$14.26−2.79%
- AMROAmaero$5.84+7.75%
- FLSCFrazier Life Sciences Acquisition Corp. II$10.30+0.29%
- TRXBTRex Bio$13.81−10.90%
- RTSNRetension Pharmaceuticals$15.25−1.61%
- PAXGUPine Tree Acquisition$10.01+0.05%
- PORTUSouthport Acquisition Corp. IIListed Oct 1, 2026
- CHWMChilwa Minerals$5.13−0.77%
- ACCVAccelevation Holdings$12.38+1.06%
- RZAIROZE AI$10.92−1.89%
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.